Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06357520 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT06357520 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 14 participants, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06357520, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat.

Conditions Studied

Interventions

  • DRUG Itraconazole
  • DRUG Baxdrostat

Study Locations (1)

Maryland

  • Research Site - Brooklyn

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2024-04-16
Est. Completion 2024-06-17
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT06357520

The ClinicalTrials.gov registry entry for NCT06357520 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (79% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Itraconazole is the first listed.

NCT06357520 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06357520 about?

NCT06357520 is a clinical study titled "A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants". The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat.

What is the current status of trial NCT06357520?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-04-16. Estimated completion is 2024-06-17.

What conditions does trial NCT06357520 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT06357520?

The interventions under investigation include: Itraconazole (DRUG), Baxdrostat (DRUG).

Who is sponsoring clinical trial NCT06357520?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06357520 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.